bearish
Global Cord Blood (CO US): Overhangs Persist; Weak Q2 Results Adds to Woe
453 Views26 Nov 2021 23:30
SUMMARY
- Global Cord Blood (CO US) shares are trading within a range and are expected to have limited upsides due to ongoing merger and policy overhangs.
- The ongoing acquisition proposal from Haitong values the company at a steep discount to the peers and one recently concluded deal in the similar space.
- The company reported muted Q2 results with flat q/q revenue growth and new subscriber adds. Surge in new Covid cases in China may prolong the business recovery.
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Top Quartile
Tina Banerjee
Global Healthcare Analyst
Price Chart(Sign Up to Access)
- Global Cord Blood (CO US): Fate Seems to Be Changing as New Growth Engine Added30 Apr 2022
- Global Cord Blood (CO US): Gloomy Regulatory and Business Environment Explain Cheap Valuation08 Apr 2022
- Global Cord Blood (CO US): No Immediate Respite Is Seen30 Jan 2022
- Global Cord Blood (CO US): Overhangs Persist; Weak Q2 Results Adds to Woe26 Nov 2021
- Global Cord Blood: Haitong Raids The Bank16 Mar 2021
x